It is 'highly unusual' for policy-makers to deviate from the long-standing application of an established policy for one issue and then revert back to the established policy until further questioned. …
Latest Video
New Stories
-
Tour de Cure backs further development of Noxopharm's preclinical brain cancer candidate
April 24, 2024 - - Latest News -
Novartis nominates ex-BMS chief executive as its new chair
April 24, 2024 - - Latest News -
'The Pharmac system again, over about 33 years old, hasn’t really changed and evolved'
April 24, 2024 - - Latest News -
AusBiotech appoints experienced Sanofi leader as its new chief executive
April 23, 2024 - - Latest News -
Should principles such as 'equity' and 'opportunity cost' be applied consistently or not at all?
April 23, 2024 - - Latest News -
Rare Cancers Australia welcomes new appointments to its board of directors
April 23, 2024 - - Latest News -
BMS and Australian venture capital firm back immunotherapy company Pathios Therapeutics
April 23, 2024 - - Latest News